Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism

Seminars in Dialysis

Volumn 18, Issue 3, 2005, Pages 171-174

  González, Esther A ^a   Al Aly, Ziyad ^a   Martin, Kevin J ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; DOXERCALCIFEROL; LANTHANUM CARBONATE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; VITAMIN D; VITAMIN D DERIVATIVE;

BONE METABOLISM; DECISION MAKING; DISEASE ASSOCIATION; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HORMONE DETERMINATION; HUMAN; HYPERPARATHYROIDISM; KIDNEY DISEASE; KIDNEY FAILURE; MINERAL METABOLISM; NONHUMAN; OUTCOMES RESEARCH; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; VITAMIN D DEFICIENCY;

BONE DISEASES, METABOLIC; ERGOCALCIFEROLS; GUIDELINE ADHERENCE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; PHOSPHATES; PRACTICE GUIDELINES; VITAMIN D DEFICIENCY;

EID: 20544454243     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2005.18302.x     Document Type: Review

References (38)

1. Malluche H, Ritz E, Lange H: Bone histology in incipient and advanced renal failure. Kidney Int 9:355-362, 1976
2. Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, Bonucci E, Taggi F: Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant 11:813-819, 1996
3. Martinez I, Saracho R, Montenegro J, Llach F: The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29:496-502, 1997
4. Martin KJ, Gonzalez EA, Slatopolsky E: Renal osteodystrophy. In: Brenner BM (ed). The Kidney, vol. 2, 7th ed. Philadelphia: WB Saunders, 2004:2255-2304
5. Eknoyan G, Levin A, Levin NW: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1-201, 2003
6. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ: Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 24:503-510, 2004
7. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218, 2004
8. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2000
9. Slatopolsky E, Brown A, Dusso A: Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37:S54-S57, 2001
10. Chertow GM, Burke SK, Dillon MA, Slatopolsky E: Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 14:2907-2914, 1999
11. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
12. Martin KJ, Gonzalez EA: Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. Semin Nephrol 24:456-459, 2004
13. Slatopolsky E: The interaction of parathyroid hormone and aluminum in renal osteodystrophy [clinical conference]. Kidney Int 31:842-854, 1987
14. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26:852-860, 1995
15. Finch JL, Brown AJ, Slatopolsky E: Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 10:980-985, 1999
16. Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E: Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40:1283-1288, 2002
17. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D: Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 38:S51-S56, 2001
18. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483-1490, 2003
19. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446-456, 2003
20. Maung HM, Elangovan L, Frazao JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW: Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 37:532-543, 2001
21. Erben RG, Bante U, Birner H, Stangassinger M: 1alpha-hydroxy vitamin D2 partially dissociates between preservation of cancellous bone mass and effects on calcium homeostasis in ovariectomized rats. Calcif Tissue Int 60:449-456, 1997
22. Sjoden G, Lindgren JU, DeLuca HF: Antirachitic activity of 1 alpha-hydroxyergocalciferol and 1 alpha-hydroxycholecalciferol in rats. J Nutr 114:2043-2046, 1984
23. Sjoden G, Smith C, Lindgren U, DeLuca HF: 1 alpha-hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 178:432-436, 1985
24. Hirata M, Katsumata K, Endo K, Fukushima N, Ohkawa H, Fukagawa M: In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)(2) vitamin D(3). Nephrol Dial Transplant 18:1770-1776, 2003
25. Ramirez JA, Emmett M, White MG, Fathi N, Santa Ana CA, Morawski SG, Fordtran JS: The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int 30:753-759, 1986
26. Al Aly Z, Gonzalez EA, Martin KJ, Gellens ME: Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol 24:422-426, 2004
27. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436-445, 2000
28. Goodman WG: Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. Nephrol Dial Transplant 17:204-207, 2002
29. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drucke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525, 2004
30. Martin KJ, Gonzalez EA: The evolution of assays for parathyroid hormone. Curr Opin Nephrol Hypertens 10:569-574, 2001
31. Gao P, Scheibel S, D'Amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL: Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605-614, 2001
32. Goodman WG, Juppner H, Salusky IB, Sherrard DJ: Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int 63:1-11, 2003
33. Goodman WG, Salusky IB, Juppner H: New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments. Nephrol Dial Transplant 17:1731-1736, 2002
34. Martin KJ, Akhtar I, Gonzalez EA: Parathyroid hormone: new assays, new receptors. Semin Nephrol 24:3-9, 2004
35. Langub MC, Monier-Faugere MC, Wang G, Williams JP, Koszewski NJ, Malluche HH: Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 144:1135-1138, 2003
36. Divieti P, Inomata N, Chapin K, Singh R, Juppner H, Bringhurst FR: Receptors for the carboxyl-terminal region of PTH(1-84) are highly expressed in osteocytic cells. Endocrinology 142:916-925, 2001
37. Divieti P, John MR, Juppner H, Bringhurst FR: Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 143:171-176, 2002
38. Murray TM, Rao LG, Muzaffar SA, Ly H: Human parathyroid hormone carboxyterminal peptide (53-84) stimulates alkaline phosphatase activity in dexamethasone-treated rat osteosarcoma cells in vitro. Endocrinology 124:1097-1099, 1989